Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical (Nasdaq: OM) announces the departure of CFO Rebecca Chambers effective July 16, 2021, with Nabeel Ahmed stepping in as Interim CFO. The company predicts Q2 2021 net revenue between $24.5M to $25.0M, marking a remarkable growth of 109% to 113% year-over-year. Leslie Trigg, CEO, expresses gratitude towards Chambers for her contributions and confidence in Ahmed’s capabilities, given his extensive finance experience. Outset’s technology aims to simplify dialysis, enhancing patient care and operational efficiency.
Outset Medical, Inc. (Nasdaq: OM) has appointed Jean-Olivier Racine as Chief Technology Officer to lead advancements in its dialysis technology. Racine brings over two decades of experience, including roles at Amazon Web Services and expertise in health data services. He aims to enhance patient care and operational efficiency utilizing data-driven innovation. Outset’s FDA-cleared Tablo Hemodialysis System, known for its two-way wireless data transmission, allows real-time data sharing, aiding in analytics and service improvements. Racine's focus will support the unique capabilities of Tablo in transforming dialysis care.
Strive Health, a leader in value-based kidney care, and Outset Medical, Inc. (Nasdaq: OM), a dialysis innovator, have partnered to enhance kidney care. Strive aims to reduce hospitalizations for kidney disease patients using Outset's Tablo Hemodialysis System for home dialysis. The collaboration focuses on delivering high-quality patient care and integrating predictive analytics. Strive recently launched a new dialysis facility in Owensboro, KY, emphasizing holistic kidney management. This partnership aims to improve patient experience and accessibility to home dialysis services.
Satellite Healthcare and Outset Medical (Nasdaq: OM) announced a multi-year sales agreement to enhance home hemodialysis adoption across Satellite Healthcare's dialysis centers. The agreement involves the purchase of Tablo systems for home use and collaboration on educational initiatives to increase patient awareness. Satellite Healthcare aims to lead in at-home dialysis treatment, serving over 8,000 patients annually. Factors such as Medicare Advantage eligibility and increased telehealth usage are expected to drive growth in home dialysis.
Outset Medical, Inc. (Nasdaq: OM), a medical technology innovator, announced its management's participation in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 7:30am PT / 10:30am ET. The event will be available via live and archived webcast on Outset's investors page. Outset's flagship product, the Tablo Hemodialysis System, offers a groundbreaking solution to streamline dialysis delivery, ensuring it can be provided anywhere and anytime, significantly enhancing patient care and reducing costs.
Outset Medical, Inc. (Nasdaq: OM) appoints Katie Szyman to its board of directors. With over 30 years of experience, Szyman has a proven track record in global medtech, significantly growing businesses at Edwards Lifesciences and Medtronic. As VP at Edwards, she increased critical care revenue by nearly 50% to $800M in six years. Szyman aims to help Outset accelerate its growth and transformation in dialysis care delivery. Outset’s innovative Tablo™ Hemodialysis System simplifies dialysis, making it accessible in various settings.
Outset Medical (Nasdaq:OM) has joined the Moving Health Home coalition, aimed at transforming home healthcare by influencing policy changes. This initiative highlights the importance of home-based care, especially post-COVID-19, allowing patients to manage chronic diseases at home. Outset's Tablo Hemodialysis System offers a compact, user-friendly solution for dialysis, enabling patients to reclaim their autonomy. The coalition's goal is to advocate for legislative support to enhance home healthcare access, aligning with Outset's mission to improve patient outcomes and reduce healthcare costs.
Outset Medical, Inc. (OM) reported a significant first quarter in 2021 with net revenues of $22.9 million, up 219% from the prior year. The Company achieved a gross margin of 1.3%, improving from a gross loss of (49.6%) in Q1 2020. Operating expenses rose to $30.0 million, resulting in a net loss of ($30.0 million) or ($0.70) per share. Positive news includes strong demand for its Tablo system, leading to an updated revenue guidance of $92 million to $97 million for 2021, reflecting an 84% to 94% growth.
Outset Medical, Inc. (Nasdaq: OM) will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 11:45am PT / 2:45pm ET. The event aims to discuss the company’s innovative dialysis technology, the Tablo Hemodialysis System, which simplifies dialysis treatment and enhances patient experience. A live and archived webcast will be available on Outset's website. This system allows for greater accessibility and efficiency in dialysis care, operating from hospital to home.
Outset Medical, Inc. (Nasdaq: OM) will announce its Q1 2021 financial results on May 5, 2021, after market close. A conference call with CEO Leslie Trigg and CFO Rebecca Chambers is scheduled for the same day at 2:00 PM PT (5:00 PM ET) to discuss these results. Outset is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis treatment and reduce costs, allowing for flexibility in care delivery from hospitals to home settings.